Sangamo Therapeutics Inc (NASDAQ:SGMO) – Research analysts at Jefferies Financial Group cut their FY2022 earnings per share estimates for Sangamo Therapeutics in a research note issued on Monday, November 12th. Jefferies Financial Group analyst M. Raycroft now anticipates that the biopharmaceutical company will earn $0.91 per share for the year, down from their prior estimate of $1.00.

Several other equities research analysts have also recently weighed in on the company. BidaskClub upgraded Sangamo Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, October 2nd. Cowen reiterated a “buy” rating on shares of Sangamo Therapeutics in a research report on Monday, July 23rd. Zacks Investment Research upgraded Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, August 14th. ValuEngine cut Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, September 6th. Finally, Wedbush reiterated a “hold” rating and set a $10.00 price target on shares of Sangamo Therapeutics in a research report on Thursday, August 9th. One research analyst has rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $19.57.

Shares of SGMO opened at $10.36 on Wednesday. Sangamo Therapeutics has a twelve month low of $9.00 and a twelve month high of $27.50. The stock has a market cap of $1.02 billion, a PE ratio of -14.80 and a beta of 3.21. The company has a current ratio of 6.32, a quick ratio of 6.32 and a debt-to-equity ratio of 0.07.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.02. Sangamo Therapeutics had a negative return on equity of 22.06% and a negative net margin of 88.78%. The firm had revenue of $23.56 million for the quarter, compared to analysts’ expectations of $26.96 million. During the same period in the prior year, the business posted ($0.15) earnings per share. The company’s revenue was up 99.5% on a year-over-year basis.

Several hedge funds have recently bought and sold shares of the stock. Sector Gamma AS boosted its stake in shares of Sangamo Therapeutics by 6.1% during the third quarter. Sector Gamma AS now owns 154,960 shares of the biopharmaceutical company’s stock valued at $2,627,000 after purchasing an additional 8,960 shares during the period. MetLife Investment Advisors LLC boosted its stake in shares of Sangamo Therapeutics by 55.2% during the third quarter. MetLife Investment Advisors LLC now owns 73,166 shares of the biopharmaceutical company’s stock valued at $1,240,000 after purchasing an additional 26,009 shares during the period. First Light Asset Management LLC boosted its stake in shares of Sangamo Therapeutics by 71.1% during the third quarter. First Light Asset Management LLC now owns 265,877 shares of the biopharmaceutical company’s stock valued at $4,507,000 after purchasing an additional 110,529 shares during the period. Pacer Advisors Inc. purchased a new stake in shares of Sangamo Therapeutics during the third quarter valued at approximately $279,000. Finally, Capital Fund Management S.A. purchased a new stake in shares of Sangamo Therapeutics during the third quarter valued at approximately $4,637,000. Institutional investors own 63.97% of the company’s stock.

In related news, Director H Stewart Parker acquired 2,000 shares of the firm’s stock in a transaction that occurred on Friday, September 7th. The shares were bought at an average cost of $13.52 per share, for a total transaction of $27,040.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Edward R. Conner sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, September 6th. The stock was sold at an average price of $14.17, for a total transaction of $70,850.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 25,000 shares of company stock worth $355,400. Company insiders own 1.20% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.

Featured Story: What is a Reverse Stock Split?

Earnings History and Estimates for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.